Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer - guidance (TA509)

National Institute for Health and Care Excellence - NICE
Publication date:
07 March 2018


Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: September 2022